Skip to main content Skip to section navigation Skip to footer
Mineralys Therapeutics, Inc.
  • About
  • Team
  • Investor Relations
  • Publications
  • News
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • SEC Filings
    • All SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Sep 14, 2023 4:05 pm EDT

Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

Sep 11, 2023 4:05 pm EDT

Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023

Sep 10, 2023 7:47 am EDT

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

Sep 10, 2023 7:45 am EDT

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

Sep 05, 2023 4:05 pm EDT

Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions

Aug 29, 2023 4:05 pm EDT

Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023

Aug 07, 2023 4:05 pm EDT

Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 31, 2023 4:05 pm EDT

Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023

Jul 17, 2023 4:01 pm EDT

Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)

May 31, 2023 8:00 am EDT

Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference

  • Page 1
  • Page 2
  • Page 3
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2023 Mineralys Therapeutics, LLC
  • Terms & Conditions
  • Privacy Policy
  • Twitter
  • Linkedin